Abstract
Alzheimer's, Parkinson's, and Huntington's disease are complex neurodegenerative conditions with high prevalence character-ized by protein misfolding and deposition in the brain. Considerable progress has been made in the last two decades in identifying the genes and proteins responsible for several human ‘proteinopathies’. A wide variety of wild type and mutant proteins associated with neu-rodegenerative conditions are structurally unstable, misfolded, and acquire conformations rich in ß-sheets (ß-state). These conformers form highly toxic self-assemblies that kill the neurons in stereotypical patterns. Unfortunately, the detailed understanding of the molecu-lar and cellular perturbations caused by these proteins has not produced a single disease-modifying therapy. More than a decade ago, sev-eral groups demonstrated that human proteinopathies reproduce critical features of the disease in transgenic flies, including protein mis-folding, aggregation, and neurotoxicity. These in itial reports led to an explosion of research that has contributed to a better understanding of the molecular mechanisms regulating conformational dynamics and neurotoxic cascades. To remain relevant in this competitive envi-ronment, Drosophila models will need to expand their flexible, innovative, and multidisciplinary approaches to find new discoveries and translational applications.
Keywords: Drosophila models, neurodegeneration, protein misfolding, amyloids, Alzheimer, Parkinson, Huntington, Prion, proteinopathies, neurotoxicity
Current Pharmaceutical Design
Title: Drosophila Models of Proteinopathies: the Little Fly that Could
Volume: 18 Issue: 8
Author(s): Diego E. Rincon-Limas, Kurt Jensen and Pedro Fernandez-Funez*
Affiliation:
- Department of Neurology, 100 S. Newell Drive, McKnight Brain Institute, University of Florida, Gainesville, FL 32610-0236,United States
Keywords: Drosophila models, neurodegeneration, protein misfolding, amyloids, Alzheimer, Parkinson, Huntington, Prion, proteinopathies, neurotoxicity
Abstract: Alzheimer's, Parkinson's, and Huntington's disease are complex neurodegenerative conditions with high prevalence character-ized by protein misfolding and deposition in the brain. Considerable progress has been made in the last two decades in identifying the genes and proteins responsible for several human ‘proteinopathies’. A wide variety of wild type and mutant proteins associated with neu-rodegenerative conditions are structurally unstable, misfolded, and acquire conformations rich in ß-sheets (ß-state). These conformers form highly toxic self-assemblies that kill the neurons in stereotypical patterns. Unfortunately, the detailed understanding of the molecu-lar and cellular perturbations caused by these proteins has not produced a single disease-modifying therapy. More than a decade ago, sev-eral groups demonstrated that human proteinopathies reproduce critical features of the disease in transgenic flies, including protein mis-folding, aggregation, and neurotoxicity. These in itial reports led to an explosion of research that has contributed to a better understanding of the molecular mechanisms regulating conformational dynamics and neurotoxic cascades. To remain relevant in this competitive envi-ronment, Drosophila models will need to expand their flexible, innovative, and multidisciplinary approaches to find new discoveries and translational applications.
Export Options
About this article
Cite this article as:
Rincon-Limas Diego E. , Jensen Kurt and Fernandez-Funez Pedro*, Drosophila Models of Proteinopathies: the Little Fly that Could, Current Pharmaceutical Design 2012; 18 (8) . https://dx.doi.org/10.2174/138161212799315894
DOI https://dx.doi.org/10.2174/138161212799315894 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthetic Pulmonary Surfactant Preparations: New Developments and Future Trends
Current Medicinal Chemistry Eugenol Elicits Prolongevity by Increasing Resistance to Oxidative Stress in <i>C. elegans</i>
CNS & Neurological Disorders - Drug Targets Protein-Protein Interactions in RSV Assembly: Potential Targets for Attenuating RSV Strains
Infectious Disorders - Drug Targets Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy Adsorption and Bioactivity of Tyrosine Hydroxylase on Gold Surfaces and Nanoparticles
Protein & Peptide Letters Ion Transporters in Brain Tumors
Current Medicinal Chemistry Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease
Current Neuropharmacology Endothelial Microparticles: Mediators or Markers of Endothelial Cell Dysfunction?
Current Hypertension Reviews Conference Report: Summary Report of the International Association of Neurorestoratology VII Conference: Regulations, Ethics, Science, and the Need of Patients Care in Neurorestoratology
CNS & Neurological Disorders - Drug Targets Current Strategies and Future Perspective for the Effective Treatment of Diabetic Retinopathy
Current Drug Therapy Biochemical Screening for in utero Drug Exposure
Drug Metabolism Letters Sensory-Motor Integration in the Medial Medulla
Current Neuropharmacology Molecule of the Month
Current Topics in Medicinal Chemistry Does Human Alpha-Synuclein Behave Like Prions?
CNS & Neurological Disorders - Drug Targets Dopamine Receptor Interacting Proteins: Targeting Neuronal Calcium Sensor-1/D2 Dopamine Receptor Interaction for Antipsychotic Drug Development
Current Drug Targets Phenolic Compounds from Plants as Nitric Oxide Production Inhibitors
Current Medicinal Chemistry Nanoporous Alumina Fabrication: A Short Review
Nanoscience & Nanotechnology-Asia Synthesis of 2`-hydroxy-4`-isoprenyloxychalcone Derivatives with Potential Antidepressant-like Activity
Medicinal Chemistry Neurokinin Peptides and Neurokinin Receptors as Potential Therapeutic Intervention Targets of Basal Ganglia in the Prevention and Treatment of Parkinsons Disease
Current Drug Targets Fibroblast Growth Factor-Inducible 14: Multiple Roles in Tumor Metastasis
Current Molecular Medicine